Analyst Edward White of H.C. Wainwright reiterated a Buy rating on Sensei Biotherapeutics (SNSE – Research Report), retaining the price target of $4.00.
Edward White’s rating is based on the promising preliminary results from Sensei Biotherapeutics’ Phase 1/2 trial of solnerstotug, a monoclonal antibody targeting VISTA. The trial showed a notable disease control rate in patients with ‘hot’ tumors, with some achieving complete or partial responses, indicating the potential efficacy of the treatment. Additionally, solnerstotug was well tolerated, with manageable side effects, enhancing its appeal as a therapeutic option.
White also considers the financial projections and market potential of solnerstotug, forecasting its launch in 2029 with significant revenue expectations. The valuation is supported by a probability-adjusted revenue model and a price/sales multiple in line with industry peers. Despite inherent risks, these factors collectively contribute to the Buy rating and a price target of $4.00.